FindMyKOL

Lakshminarayanan Nandagopal

Basic profile

Hematology Oncology Associates of Fredericksburg

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionFredericksburg, VA · SoutheastSpecialtyHematology / OncologyFocusOncology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Lakshminarayanan Nandagopal is an Oncology physician affiliated with Hematology Oncology Associates of Fredericksburg. OpenAlex indexes 42 publications with 1,852 citations (h-index 11).

Overview

Scholarship

indexed output and impact (OpenAlex)
42publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

1,852citations

Citations across these publications.

11h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
72companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

72 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • AstraZeneca
    Program year20252 paymentsResearch
    $101,072
  • BioNTech SE
    Program year20255 paymentsResearch
    $19,490
  • Aadi Bioscience
    Program year20252 paymentsResearch
    $15,062
All 182 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    46.9%
    Iron, parenteral preparations46.5%
    Ferric carboxymaltose100%
    Part B, office-administered≥124 patients
    Erythropoiesis-stimulating Agent0.4%
    Epoetin alfa100%
    Part B, office-administered≥16 patients

    + 1 more class in this area

  • Cancer & immunology

    31.3%
    PD-1 inhibitor15.6%
    Nivolumab54%Pembrolizumab46%
    Part B, office-administered≥34 patients
    Microtubule Inhibitor4.3%
    Paclitaxel protein-bound particles54%Paclitaxel46%
    Part B, office-administered≥19 patients

    + 9 more classes in this area

  • Metabolism & gastrointestinal

    10.8%
    Substance P/Neurokinin-1 Receptor Antagonist6.5%
    Aprepitant100%
    Part B, office-administered≥47 patients
    Other antiemetics1.8%
    Fosaprepitant100%
    Part B, office-administered≥16 patients

    + 5 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”